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Abstract Ependymomas are common pediatric brain tumors
that originate from the ependyma and characterized by poor
prognosis due to frequent recurrence. However, the current
WHO grading system fails to accurately predict outcome. In
a retrospective study, we analyzed 54 intracranial pediatric
ependymomas and found a significantly higher overall surviv-
al in supratentorial cases when compared to infratentorial tu-
mors. Next we performed region-specific immunohistochem-
ical analysis of the ependyma in neonatal and adult ependyma
from the central canal of spinal cord to the choroid plexus of
lateral ventricles for components of cell-cell junctions
including cadherins, claudins and occludin. We found robust
claudin-5 expression in the choroid plexus epithelia but not in
other compartments of the ependyma. Ultrastructural studies
demonstrated distinct regional differences in cell-cell junction
organization. Surprisingly, we found that 9 out of 20
supratentorial but not infratentorial ependymomas expressed
high levels of the brain endothelial tight junction component
claudin-5 in tumor cells. Importantly, we observed an in-
creased overall survival in claudin-5 expressing supratentorial
ependymoma. Our data indicates that claudin-5 expressing
ependymomas may follow a distinct course of disease. The
assessment of claudin-5 expression in ependymoma has the
potential to become a useful prognostic marker in this pediat-
ric malignancy.
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Introduction
Ependymomas are the third most common central nervous
system (CNS) malignancies in children [1]. The majority of
the cases is located in the posterior fossa [2, 3], however in the
first years of life they often appear supratentorial [4].
According to the WHO CNS tumor classification ependymal
tumors are grouped into grade I (subependymoma,
myxopapillary ependymoma), II (ependymoma) and III
(anaplastic ependymoma) [5] Whereas patients with
subependymoma and myxopapillary ependymoma have in
general a very good prognosis, grade II and grade III
ependymomas have a relatively poor outcome [6]. The path-
ological criteria for differentiation between grade II and III are
difficult to apply and thus, their prognostic significance is of
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uncertain clinical utility [7]. Despite the fact that an array of
histological or immunohistochemical markers have been pro-
posed as prognostic factors [8–10], currently the prognostica-
tion of ependymoma is based only on clinical parameters i.e.
age at diagnosis and extent of resection, with patients under
2 years of age and patients with residual tumor after surgery
having a significantly poorer outcome [11, 12]. Thus knowl-
edge about biological processes involved in ependymoma on-
cogenesis and novel biological prognostic and predictive
markers are urgently needed [13]. Furthermore, different mo-
lecular changes associated with patient outcome have been
detected by genetic studies [14–19] and different molecular
subgroups with specific genomic alterations were identified.
However, the application of these molecular subgroups in
clinical practice is still limited [15, 19]. One major concern
is the fact that most of the clinical studies on ependymoma
included pediatric and adult cases and statistical analysis
was often performed in these combined cohorts. However, it is
now obvious that the course of the disease is different in pe-
diatric and adult cases as it is reflected by a number of
clinicopathological parameters. For instance in adult
ependymomas supratentorial location is indicator of a worse
prognosis while the limited number of studies with pediatric
cases does not support this observation [9, 11]. It has also been
demonstrated in a large cohort of pediatric and adult cases that
potential histological prognosticators have a localization de-
pendent role [20]. A recent study suggested that anaplastic
morphology has a prognostic significance in pediatric
infratentorial ependymomas [21].
The local invasive potential of cancer cells is critically de-
termined by the cell-cell adhesion. In brain tumors the dysreg-
ulation of cell-cell adhesion proteins is a prerequisite for the
invasion of the surrounding neural tissue [22, 23]. Claudins
are pivotal components of the tight junction cell-cell adhesion
complex. Currently 24 genes had been identified in the human
genome that encodes claudins [24]. They regulate the
paracellular barrier between the cells and thus the exchange
of compounds through the intercellular junction. Claudin-1,
claudin-2, claudin-5, claudin-7, claudin-11 and claudin-12
have so far been described in the central nervous system
[25–27]. Claudin-5 and claudin-12 have been characterized
as the only claudins of the brain endothelial cells suggesting
a critical role in the formation of the blood brain barrier (BBB)
[28]. Nevertheless, a number of claudins had been implicated
in CNS tumorigenesis including claudin-1 and claudin-3
[29–32]. The potential clinical relevance of the expression of
certain claudins (2–5, 7 and 10) expression was also studied in
ependymomas and it is now evident that claudins can influ-
ence ependymoma cell growth [33].
There are certain regional differences described in the tight
junction morphology and physiology of the ependymal epi-
thelial cells lining the ventricular system including the choroid
plexus. However, most of these studies have been performed
in the rodent CNS [34–36]. A recent study indicated that there
are important differences relevant to CNS tumor formation
between mice and human ventricular zones [37]. However,
these variations are not fully understood. Furthermore the
BBB is not a tightly sealed system but there are specific re-
gions that allow the direct contact of certain neurons with the
cerebrospinal fluid (CSF) [38, 39]. Data on the molecular
background of these spatial differences could contribute to
the understanding of tumorigenesis and help to design more
specific and thus efficient treatment options for pediatric
ependymomas.
Accordingly, we analyzed the prognostic power of certain
clinicopathological parameters and sought to characterize the
expression of cell-cell adhesion proteins in normal ependyma
as well as in pediatric ependymomas. Here we show that
claudin-5 is highly expressed in the choroid plexus epithelium
and in a subset of supratentorial ependymomas. Furthermore,
we provide data about the influence of claudin-5 expression
on overall survival in supratentorial pediatric ependymomas.
Material and Methods
Patients
The formalin fixed paraffin embedded (FFPE) histopatholog-
ical samples from 54 pediatric patients with intracranial
ependymomas were collected between 1997 and 2006 at the
National Institute of Neurosurgery, Budapest, Hungary and
between 1980 and 2000 at the Medical University of
Vienna, Vienna, Austria. All histological samples were obtain-
ed from the initial surgery. No patients received radiation or
chemotherapy therapy prior to the surgery. The average and
median age of patients at the time of operation was 6.1 and
5 years, respectively (ranging from 8 months to 17 years). The
average follow-up period was 6.8 years ranging from 2 weeks
to 16.7 years.
Ependyma Samples
Samples were collected from the routine autopsy of deceased
newborns (35 to 40 gestation weeks). Subjects with central
nervous system associated diseases were excluded from the
study. The samples were collected in all cases from the right
lateral, third and fourth ventricles and from the upper two
segments of the cervical spinal cord. During careful anatom-
ical opening of the ventricular system about 1 cm3 sized
blocks were excised from the head of the caudate nucleus,
choroid glomus attached to the crus of fornix, pes hippocampi,
third ventricular surface of the thalamus and the medial emi-
nence of the rhomboid fossa. Special care was taken to avoid
damaging of the ependymal surface of the specimens. Choroid
plexus tissue was also removed from the right lateral ventricle.
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Immunohistochemistry
Representative paraffin blocks - defined as those with the
largest amount of viable and anaplastic tumor - for each tumor
were selected. Immunohistochemistry was performed on the
tumor tissues and the neonatal ependyma and choroid plexus.
The immunohistochemical reactions were performed on 3 μm
sections obtained from the FFPE blocks. After the
deparaffinization steps, the slides were treated in a microwave
oven in Target Retrieval Solution (S1699 from DAKO,
Carpenteria, CA, USA) for 30 min for heat-induced epitope
retrieval. The immunohistochemical reactions were per-
formed in an automated Ventana ES Immunostainer System
(Ventana Medical Systems Inc., Tucson, AZ, USA) with the
solutions and steps according to the manufacturer. The follow-
ing antibodies and dilutions were used: claudin-1 (1:80,
Zymed, #18–7362), claudin-2 (1:20, Zymed, #18–7363),
claudin-5 (1:120, Zymed, #18–7364), claudin-7 (1:100,
Zymed, #34–9100), E-cadherin (1:500, Dako #M3612), N-
cadherin (1:300, Abcam #12,221), occludin (1:250,
Invitrogen, Carlsbad, CA, USA ) and vimentin (1:300, Dako
#M0725). The slides were counterstained withMayer’s hema-
toxylin (Zymed, South San Fransisco, CA, USA). Positive
controls and negative control tissues (with the omission of
the primary antibodies) were included in every run.
Quantitative Real-Time PCR
Total RNAwas isolated from ten macrodissected five-micron
thick sections of FFPE blocks using RNeasy FFPE Kit accord-
ing to the manufacturer’s instructions (QIAGEN, Hilden,
Germany). The quantity and quality of the RNA was deter-
mined by NanoDrop. 400 nanogram of total RNA was used
to perform reverse transcription using High Capacity RNA-to-
cDNA Kit (Applied Biosystems Life Technologies, Carlsbad,
CA, USA). Thirty nanograms of cDNA were used as a tem-
plate for the real-time PCR using Power SYBR Green PCR
Master Mix SYBRGreen on an ABI Prism 7000 Sequence
Detection System. The following previously described
claudin-5 and ABL primers were used: (5´ TTC CTG AAG
TGG TGT CAC CTG AAC), reverse (5´ TGG CAG CTC
TCA ATC TTC ACA G); forward (5´ ACG AGT CTG GTT
GAT GCT GTG), reverse (5´ GGC GGA CTG TGG CTT
TGG), respectively [40]. PCR reactions without cDNA sam-
ples were used as negative controls. Each reaction was per-
formed in duplicate. The fluorescent data were converted into
cycle threshold (CT) measurements, and the DDCT method
was used to calculate expression relative to the internal control.
Transmission Electronmicroscopy
Samples collected for ultrastructural studies were fixed in PBS
containing 1 % paraformaldehyde and 1 % glutaraldehyde for
2 days at room temperature. Next, we dissected approximately
1 mm3 ependyma or choroid plexus containing tissue pieces
that were transferred to calcium-cacodylate (Merck) for 3×
30 min and treated with 1 % OsO4 in cacodylate puffer for
2 h at 4 degree. Following washes with cacodylate solution
(3 × 15 min) the samples were dehydrated in an ascending
series of ethanol (30 %, 96 % and 100 % 2 × 30 min) and
propylene oxide, propylene oxide-araldit, and embedded in
Durcupan (ACM; Fluka, Buchs, Switzerland) at 56 degree
for 2 days. A series of consecutive ultrathin sections (80 nm
thick) were collected on Formvar-coated single-slot grids and
contrasted by 6 % uranyl acetate in 50 % ethanol for 20 min
and counterstained with lead citrate for 10 min. Electron mi-
crographs were taken at a Hitachi (Yokohama, Japan) electron
microscope.
Statistics
The significance of the quantitative RT-PCR data was deter-
mined by Mann-Whitney test. The infratentorial and
supratentorial group was compared by Mann-Whitney test
and by χ2-test. Kaplan-Meier curves for overall survival were
evaluated for the extent of resection, grade, tumor localization
and claudin-5 expression in ependymoma cells for all patients
in the study. Statistical significance (P < 0.05) was determined
by log-rank test using GraphPad Prism 5.0 software
(GraphPad Inc., San Diego, CA).
Results
Radical Resection and Supratentorial Localization Are
Positive Prognosticators
Out of the 54 patients, 33 (61.1 %) had undergone complete
tumor resection based on the surgeons interpretation after
completion of the procedure while in 21 cases (38.9 %) only
partial resection had been achievable. In the Kaplan-Meyer
there was a strong tendency for increased overall survival in
the total resection group (Fig. 1a, p=0.064). Twenty seven
(50 %) out of 54 tumors were categorized as grade 2 and 27
(50 %) as grade 3. There was no significant difference in
overall survival between grade 2 and grade 3 ependymomas
(Fig. 1b, p=0.35). There were 20 (37 %) supratentorial and 34
(63 %) infratentorial tumors in this series. The supratentorial
group had significantly higher average age at diagnosis
(p < 0.001) and a non-significantly higher proportion
of total resection (p = 0.15) as presented in Table 1.
There was no significant difference in the grade distri-
bution between the supratentorial and infratentorial
group (Table 1). Nevertheless, the supratentorial locali-
zation resulted in a significantly higher overall survival
(Fig. 1c, p=0.013).
Region specific differences of claudin-5 expression in pediatric intracranial ependymomas
Claudin-5 Is differentially Expressed in Neonatal
Ependymal Cells and Choroid Plexus Epithelia
We hypothesized that regional variation in the expression of
cell-cell adhesion molecules in the human ependyma may
contribute to the differences in supratentorial and
infratentorial ependymomas. We analyzed the expression of
claudins (−1,-2,-5 and −7), E- and N-cadherin and occludin.
We have collected central canal, ventricular wall and choroid
plexus tissue samples from deceased neonates. The
ependymal cell layer was identified by vimentin staining
[41]. There was no lateral labeling of claudin-5 in any regions
of the ventricular lining (Fig. 2). Interestingly choroid plexus
epithelia displayed a very intense claudin-5 staining (Fig. 2).
We could also demonstrate the expression of the other protein
components of the tight junction complex including claudin-1,
claudin-2 and occludin, but not claudin-7 in choroid plexus
epithelia (Fig. 3).
Distinct Ultrastructural Composition of Cell-Cell Junction
in Neonatal Ependyma and Choroid Plexus Epithelium
Next we sought to analyze whether regional differences in the
expression of cell-cell junction molecules in ependyma and
choroid plexus lead to altered cell-cell junction morphology
and function. Choroid plexus epithelium and ventricular
ependymal cells possess distinct cell-cell junction complexes
in the apico-lateral plasma membrane as depicted in Fig. 4.
The ventricular ependymal cells lack tight junctions but dis-
play rather large adherent junctions. Both cell types display
microvilli on the apical surface. As expected, only the ventric-
ular ependymal cells carry cilia while the choroid plexus ep-
ithelium lacks these organelles.
Claudin-5 Is Expressed in a Subset of Supratentorial
Pediatric Ependymomas
Claudin-5 is displayed in the endothelial cells of the tumor
capillaries of the ependymoma tissue (Fig. 5a and b,
arrowheads). Importantly, in 9 (45 %) of the 20
supratentorial cases the ependymoma tumor cells
expressed claudin-5 with appropriate plasma membrane
localization (Fig. 5b). Furthermore, we could not detect
expression of claudin-1 and −2, occludin or E- and N-
cadherin in these cases suggesting that claudin-5 expres-
sion delineates a specific subset of ependymoma cases.
Importantly, none of the infratentorial ependymomas
showed claudin-5 expression (Fig. 5a). Additionally,
we have also analyzed 9 spinal ependymomas and
found no claudin-5 expression in the tumor cells (data
not shown). We next isolated total RNA from
macrodissected FFPE sections of 5 claudin-5 negative
and 6 claudin-5 positive cases. The average expression
level of claudin-5 determined by quantitative RT-PCR
was significantly increased in the positive cases
(Fig. 5c.). Importantly, other major components of the
cell-cell junction complex (claudin-1, −2, and −7, occludin,
E- and N-cadherin) did not show this region specific expres-




Fig. 1 Kaplan-Meier analysis of overall survival in pediatric intracranial
ependymomas. a, Complete surgical resection was found to be a positive
prognostic marker as expected (p = 0.064) b, Histological grade did not
predict the overall survival of patients (p = 0.35) c, Importantly,
supratentorial localization is also a positive prognostic factor in our
series (p = 0.013)
Table 1 Comparison of the infratentorial and supratentorial subgroup
Characteristics Infratentorial (N = 34) Supratentorial (N = 20) p-value
Age (years) 3.9 ± 3.1 9.7 ± 4.5 <0.001
Grade
II 17 50 % 10 50 % 1
III 17 50 % 10 50 %
Resection
Total 18 53 % 15 75 % 0.15
Subtotal 16 47 % 5 25 %
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Claudin-5 Expressing Ependymomas Tend to Display
a longer Overall Survival
Since cell-cell junction complexes are critical regulators
of tissue cohesion and influence the invasive potential
of cells we investigated whether localization and
claudin-5 expression can influence the progression of the
disease as characterized by overall survival. Interestingly, the
claudin-5 negative supratentorial cases showed a de-
creased overall survival in the Kaplan-Meier survival
analysis when compared to claudin-5 positive tumors
(Fig. 6).
Discussion
The recent revolution in molecular profiling of ependymomas
has led to the identification of new clinically relevant subsets
of tumors [15, 19, 42]. Gene expression microarray studies on
ependymoma have implicated radial glial cells as the cell of
origin for ependymomas [43]. Furthermore, a distinct molec-
ular profile has been established for ependymomas with dif-
ferent tumor grades and localization [42]. Also, distinct pat-
tern of hypermethylation was found in spinal, posterior fossa







Fourth ventricle Choroid plexusLateral ventricleFig. 2 Claudin-5 expression in
neonatal ependyma. We found no
lateral claudin-5 staining in the
ependymal cells of the ventricular
system including the infratentorial
fourth or supratentorial lateral
ventricles. The endothelial cells of
the subventricular capillaries are
claudin-5 positive (indicated by
arrowheads). In contrast, the
choroid plexus epithelium
showed intense staining along the
lateral plasmamembrane as well.
Vimentin staining identifies the




Fig. 3 Cell-cell adhesion molecules in the neonatal choroid
epithelium. Intense claudin-1 and claudin-2 labeling was observed
in the plasma membrane and to some extent in the cytosol.
Occludin staining was detected mostly in the apical region of
the cells. E-cadherin clearly localized to the lateral plasma
membrane
Fig. 4 Ultrastructural differences in the cell-cell junction in the neonatal
ependymal cell layer and choroid epithelium. Choroid plexus epithelium
and ventricular ependymal cells possess distinct cell-cell adhesion struc-
tures in the lateral plasmamembrane as indicated by arrowheads. Note the
lack of tight junctions in the ventricular ependymal cells whereas they
display adherent junctions. Both cell types carry microvilli on the apical
surface. However, in contrast to ventricular ependymal cells, the choroid
plexus epithelium lacks cilia (indicated by arrow)
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genome wide methylation and gene expression microarray
study identified novel differentially regulated genes in pediat-
ric ependymomas [45]. The gain of 1q was suggested to be
associated with survival in intracranial ependymoma, howev-
er, not all subsequent studies could confirm the prognostic
power of this genomic alteration [16, 46]. Altogether, none
of these studies yielded new molecular prognostic markers
for pediatric ependymomas so far.
Here we show that claudin-5 is expressed by choroid plex-
us epithelial cells but not by ventricular ependymal cells. So
far only claudin-1, −2, and −11 had been described in choroid
plexus epithelial cells as part of the blood-CSF barrier and
claudin-3 and claudin-5 in brain endothelial cells as a compo-
nent of the blood-brain barrier [27, 36]. The demonstrated
ultrastructural and immunohistochemical differences between
the choroid plexus epithelia and the ventricular ependymal
cells are in line with functional observations. Namely, the
ventricular ependymal cells do not form a tight barrier be-
tween the CSF and the nervous system interstitia, while the
epithelial cells of the choroid plexus form a highly regulated
barrier between the CSF and the blood vessels and thus are
major contributors to the blood-CSF barrier [34, 47].
In our study we confirmed that claudin-5 is expressed by a
subset of supratentorial ependymomas [33] and provide evi-
dence that it is not expressed in infratentorial tumors. In line
with previous findings, ependymoma retains some of the
region specific differences that can be found in the radial glial
cell populations [43]. Interestingly, a previous gene expression
signature had been established in a microarray study that
distinguished spinal, posterior fossa and supratentorial
ependymal tumors and found claudin-5 specifically
overexpressed in supratentorial cases (supplemental data in
[43]). The presence of the tight junction component claudin-
5 might contribute to increased cell-cell adhesion between the
claudin-5 expressing ependymoma tumor cells and thus inter-
fere with the invasive potential of ependymoma cells.
There is emerging evidence that the innate regional molec-
ular differences in the progenitor cell populations of the cen-
tral nervous system play a pivotal role in the development of
pediatric brain tumors [48–50]. Our observation that a subset
of supratentorial ependymomas expresses claudin-5 and dis-
plays a different biological behavior may suggest that these
ependymomas arise from a distinct progenitor population of
the human ventricular system.
Furthermore, recent studies have identified stem-cell like
tumor cells in glioblastoma tumors that formed vessel-like
structures with connection to the circulation. The expression
of a brain endothelial cell tight junction component by
ependymoma cells may suggest the existence of this kind of
molecular vascular mimicry in pediatric ependymomas.
In our series of tumors the extent of resection and the lo-
calization was found to be a prognostic factor. These observa-
tions are in line with previous studies that analyzed the prog-
nostic significance of clinicopathological variables in pediat-
ric ependymoma cases [1, 10, 21]. Similar to other studies, the
grade was not predicting the overall survival in our patient
population [51]. However, here we demonstrate that claudin-
5 expression by ependymoma cells is a potential predictor of
overall survival.
Altogether, our data show that claudin-5 expression in pe-
diatric intracranial ependymoma is a potential prognostic fac-
tor and should be further evaluated as a promising histopath-
ological biomarker. Furthermore, in prospective clinical trials
with pediatric ependymomas claudin-5 expression should also
be registered to evaluate whether this subset of ependymomas
displays a different response for adjuvant treatments.

















Fig. 5 Claudin-5 expression in pediatric intracranial ependymomas. a, In
34 infratentorial ependymomas only the brain endothelial cells expressed
claudin-5. b, In contrast, in 9 out of 20 supratentorial cases the ependymal
cells displayed plasma membrane localized claudin-5 expression. Arrows
indicate the blood vessels. c, A significant increase in claudin-5
expression was found at the transcription level by qRT-PCR (p = 0.03).
Due to the high level of endothelial cell expression even claudin-5 neg-
ative ependymoma samples contained relatively high amount of CLDN-5
mRNA
Fig. 6 Kaplan-Meier analysis of overall survival and claudin-5 expres-
sion in supratentorial pediatric ependymomas. The claudin-5 positive
supratentorial group displayed an increased overall survival when com-
pared to the claudin-5 negative supratentorial cases (p = 0.048)
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